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ABSTRACT
Objectives: Hospital-acquired acute kidney injury
(HA-AKI) is associated with a high risk of mortality.
Prediction models or rules may identify those most at
risk of HA-AKI. This study externally validated one of
the few clinical prediction rules (CPRs) derived in a
general medicine cohort using clinical information and
data from an acute hospitals electronic system on
admission: the acute kidney injury prediction score
(APS).
Design, setting and participants: External
validation in a single UK non-specialist acute hospital
(2013–2015, 12 554 episodes); four cohorts: adult
medical and general surgical populations, with and
without a known preadmission baseline serum
creatinine (SCr).
Methods: Performance assessed by discrimination
using area under the receiver operating characteristic
curves (AUCROC) and calibration.
Results: HA-AKI incidence within 7 days (kidney
disease: improving global outcomes (KDIGO) change
in SCr) was 8.1% (n=409) of medical patients with
known baseline SCr, 6.6% (n=141) in those without a
baseline, 4.9% (n=204) in surgical patients with
baseline and 4% (n=49) in those without. Across the
four cohorts AUCROC were: medical with known
baseline 0.65 (95% CIs 0.62 to 0.67) and no baseline
0.71 (0.67 to 0.75), surgical with baseline 0.66 (0.62
to 0.70) and no baseline 0.68 (0.58 to 0.75). For
calibration, in medicine and surgical cohorts with
baseline SCr, Hosmer-Lemeshow p values were non-
significant, suggesting acceptable calibration. In the
medical cohort, at a cut-off of five points on the APS
to predict HA-AKI, positive predictive value was 16%
(13–18%) and negative predictive value 94%
(93–94%). Of medical patients with HA-AKI, those
with an APS ≥5 had a significantly increased risk of
death (28% vs 18%, OR 1.8 (95% CI 1.1 to 2.9),
p=0.015).
Conclusions: On external validation the APS on
admission shows moderate discrimination and
acceptable calibration to predict HA-AKI and may be
useful as a severity marker when HA-AKI occurs.
Harnessing linked data from primary care may be one
way to achieve more accurate risk prediction.
INTRODUCTION
Acute kidney injury (AKI) is a clinically diag-
nosed syndrome deﬁned as an acute increase
in serum creatinine (SCr) and/or a reduc-
tion in urine volume.1 One in ﬁve adults
worldwide experience AKI during a hospital
admission and despite signiﬁcant develop-
ments in hospital care, mortality associated
with AKI remains high.2–7 Deﬁcits in the rec-
ognition and subsequent management of
patients who have developed AKI have been
shown,8 9 with recent studies suggest around
60–79% of AKI cases are from the commu-
nity and can be ﬂagged at admission.10–15
However, a signiﬁcant proportion of AKI
develops in hospital (hospital-acquired AKI,
HA-AKI) and systematically highlighting
patients at the highest risk of HA-AKI is of
great interest.16 17 Given that a continuum of
Strengths and limitations of this study
▪ This large study is one of the few external valida-
tions of an acute kidney injury (AKI) prediction
rule in general medical and surgical hospital
populations, including patients without a base-
line serum creatinine (SCr).
▪ Stringent inclusion criteria (stay at least one
night, first admission, repeat SCr performed),
excluded a large proportion of ‘low-risk’ patients,
recognised as such by the clinical team.
▪ Single-centre cohort, in the same geographical
area to the derivation site cautions against
generalisability.
▪ Medical histories relied on previously coded
events on the hospital database and are thus
likely to underestimate disease prevalence.
▪ Reliance on a baseline SCr that could have last
been performed a number of months ago, means
that a proportion of the patients considered to
have hospital-acquired AKI may have already ful-
filled the criteria for a change in SCr prior to
admission, that is, have community-acquired AKI.
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injury exists before loss of excretory kidney function can
be measured with standard laboratory tests (ie, SCr),
one method that could be used to highlight patients at
an earlier stage before injury is the use of prediction
models.18–21 Most prediction research involves derivation
and internal validation, however, external validation is
crucial to address overﬁtting and generalisability.22–26
The majority of HA-AKI prediction models focus on
high-risk specialist groups such as cardiac surgery with
few studies in acute medicine or surgery.15 27–29 One
such model is the acute kidney injury prediction score
(APS), derived in acute medicine patients in a single UK
centre which uses a combination of comorbidities and
acute physiological variables derived from a hospital
electronic data system (see online supplementary
appendix table A1 for variables). Discrimination
assessed by the area under the receiver operating charac-
teristic curve (AUROC) to predict HA-AKI within 7 days
was 0.72 in derivation and 0.76 in an internal validation
cohort (without a baseline SCr).15 The primary aim of
this study was to externally validate the APS in a general
medical population with a known baseline SCr. The
presence of a known baseline accurately accounts for
patients with chronic kidney disease (CKD) and there-
fore allows more conﬁdent conclusions to be drawn as
to whether acute deterioration in renal function has
already occurred at admission (community-acquired
AKI, CA-AKI). Secondary aims were validations of the
APS in (1) a general medical population without a
known baseline SCr and (2) general surgical populations
again with and without a known baseline SCr. Published
guidance for reporting were followed.22
METHODS
A retrospective observational cohort external validation
study of the APS (see online supplementary appendix
table A1 for variables and weightings) was performed on
the adult medical and surgical units of St Richard’s
Hospital site of Western Sussex Hospitals NHS
Foundation Trust (WSHFT), for the period March 2013
to February 2015. WSHFT is an 870-bed Trust on the
South Coast of England, with a combined annual emer-
gency department attendance over 150 000 and 60–80
acute medical or surgical admissions per 24-hour
period. St Richard’s is a separate hospital site from
Worthing hospital where in 2011 the APS was derived on
general medical patients. There was no cross-site con-
tamination of staff, though catchment populations for
the two sites, 20 miles apart, are similar. Surgery at the
Trust includes general surgery, urology and trauma and
orthopaedic, but does not include major trauma, neuro-
surgery, cardiac, major vascular or transplantation. (see
online supplementary appendix table A2 for clinical and
demographic values for the derivation and presented
external validation cohorts).15
At admission, all inpatients (acute medicine and
elderly care, emergency and elective surgery) routinely
had physiological observations measured and entered
via handheld systems into the clinical data software
system (Patientrack Sydney, NSW, Australia). Previous
International Statistical Classiﬁcation of Diseases 10th
revision (ICD-10) electronically coded history (heart
failure, liver disease and diabetes mellitus) were retrieved
and CKD was deﬁned as an estimated glomerular ﬁltra-
tion rate (eGFR)<60 mLs/min prior to admission (in
those with an available baseline SCr) using a National
algorithm that has been shown to perform well.30 Kidney
disease: improving global outcomes (KDIGO) criteria
for AKI was employed (SCr increase of ≥1.5 from the
admission value or ≥26.5 μmol/L within a rolling
48 hours during the ﬁrst 7 days of the patients ﬁrst
admission in the study period). Patients were included if
they were ≥18 years of age, stayed at least one night in
the medical or surgical division over the 24-month
period (2013–2015) and had at least one SCr repeated.
Exclusion criteria:
▸ patients with AKI on admission (deﬁned using
KDIGO change from baseline SCr or absolute SCr
value ≥354 μmol/L);
▸ patients moved directly from the accident and emer-
gency department (A&E) department to the inten-
sive care unit (ICU) (as neither area uses the
Patientrack data system);
▸ aged<18 years;
▸ obstetrics and gynaecology admissions;
▸ discharged without spending a night in hospital.
Patients were followed-up until discharge from hos-
pital, or death, during the inpatient spell. The analysis
was performed for the patients’ ﬁrst admission where
more than one occurred in the study period. As all
patients admitted had an APS calculated automatically
by the Patientrack© system before any outcome had
occurred, there were no missing demographic or physio-
logical data at admission. As history relied on previous
coded events (from attending hospital), potentially such
data could have been missing. None of the researchers
involved in analysis of the data were involved in the man-
agement of the patients. The research team members
responsible for data analysis had access only to the fully
anonymised individual-level data and were blinded to
other patient data, as well as to the components of the
calculated scores in the hospital information system.
Since there is no consensus on how to determine what
counts as an adequate sample size in such studies, all
available (19 276) hospital cases for the period 2013–
2015 were included in the analysis.22
Following logistic regression analysis, discrimination
was assessed by the area under the receiver operating
characteristic curve (AUROC),22 and calibration by the
Hosmer-Lemeshow (H-L) test, where a signiﬁcant
p<0.05, may indicate poor ﬁt of a rule or model, though
this has limitations in larger datasets.31 32 Calibration
was additionally assessed graphically by plotting pre-
dicted probabilities (x-axis) against the observed event
rate (y-axis) of the outcome and deriving a linear
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function (an intercept of zero and a slope of one indi-
cating perfect calibration).22 Predictive values and likeli-
hood ratios were calculated to further inform on the way
model performance could impact on clinical workload.
Following extraction, all data were fully anonymised on
Microsoft Excel and analyses performed on SPSS V.22.
RESULTS
From an initial 19 276 patient episodes in medicine
(including elderly care) and surgery (see ﬁgure 1) over
a 2-year period 12 554 episodes were analysed (n=7170
in medicine and n=5384 in surgery) after excluding
patients with AKI on admission (n=782) or with no
repeat SCr while in hospital (n=5940). Over a quarter of
patients (n=3329) had no baseline SCr. Table 1 sum-
marises the four groups in terms of clinical and demo-
graphic data. Incidence of HA-AKI was:
▸ medical patients with a known SCr baseline 8.1%;
▸ medical patients without a known baseline SCr 6.6%;
▸ surgical patients with a known baseline SCr 4.9%;
▸ surgical patients with no known baseline were 4%.
The medical cohort were signiﬁcantly older than the
surgical cohort (78 years (65–86) vs 67 (51–77), respect-
ively, p≤0.001). There was also a higher frequency of
morbidity, particularly heart failure in the medical popu-
lation who also had longer hospital stays. Inpatient mor-
tality was increased in those with HA-AKI across all four
groups, but in absolute terms this was greatest in medical
patients where in those with a baseline SCr the observed
mortality was 21.5% in those who developed HA-AKI
died versus 4.5% in those without HA-AKI (p≤0.001).
For the primary analysis in medical patients with a
baseline SCr the AUROC was 0.65 (95% CI 0.62 to 0.67)
and the H-L p=0.064. In those patients without a
Figure 1 Consort study flow chart. HA-AKI, hospital-
acquired acute kidney injury; SCr, serum creatinine.
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baseline SCr the AUROC was 0.71 (0.67 to 0.75), H-L
p=0.014. In surgical patients with baseline SCr: AUROC
0.66 (95% CI 0.62 to 0.69) and H-L p=0.093; Surgery
without SCr baseline: AUROC 0.67 (0.58 to 0.75) and
H-L p=0.664 (see ﬁgure 2).
Calibration plots (ﬁgure 3) for the association between
predicted probabilities and observed event rates in
medical and surgical cohorts (with a baseline SCr) demon-
strated agreement at low probability rates while at higher
rates calibration deviated in the medical cohort, though
the number of events were small. Table 2 compares the
predicted rates of HA-AKI (from the original derivation
study cohort) compared with observed rates in the valid-
ation medical cohort (with baseline SCr), grouped accord-
ing to APS admission score.15 The table shows in the
validation cohort 4% of patients scoring 0–2 APS points
developed HA-AKI, compared with 28% of cases scoring
≥7 points with an OR of 4.7 (95% CI 3.1 to 7.2).
At a cut-off of ﬁve points on the APS for medical
patients with baseline SCr sensitivity was 34% (30–39%),
speciﬁcity 82% (81–83%), positive predictive value
(PPV) 16% (13–18%), negative predictive value (NPV)
94% (93–95%), positive likelihood ratio (PLR) 2.1 (1.8–
2.4) and negative likelihood ratio (NLR) 0.79
(0.73-0.84). Lowering the cut-off to a score of three
points increased sensitivity to 82% (78–86%), with a
reduction in speciﬁcity to 37% (36–39%), with PPV 10%
(9–12%) and NPV 96% (95–97%), PLR 1.3 (1.25–1.38)
and NLR 0.48 (0.39–0.59).
In the medical cohort with a known baseline SCr,
HA-AKI was associated with signiﬁcantly higher inpatient
mortality using a cut-off of ﬁve points on the APS: 28%
of patients who developed HA-AKI died versus 18% with
a score <5 points (OR 1.8 (95% CI 1.1 to 2.9), p=0.015).
This was also found in patients without a baseline SCr
(mortality 42% vs 19%, p=0.029).
Figure 2 Area under the receiver operating characteristic curves for APS to predict HA-AKI. A: medicine with known baseline
SCr 0.65 (95% CI 0.62 to 0.67); B: medicine no baseline SCr 0.71 (95% CI 0.67 to 0.75); C: Surgery with known baseline SCr
0.66 (95% CI 0.62 to 0.70); D: surgery without a baseline SCr 0.67 (95% CI 0.58 to 0.75). APS, acute kidney injury (AKI)
prediction score; HA-AKI, hospital-acquired AKI; SCr, serum creatinine.
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DISCUSSION
This study represents one of the few external validations
of a prediction model for HA-AKI—the APS—for acute
general medical and surgical cohorts. Moderate discrim-
ination and satisfactory calibration were found in
cohorts with and without a known baseline SCr. External
validation addresses optimism and generalisability.22–24
33 34 Discrimination, assessed by AUROC analysis was
inferior to the derivation study (0.65 in the comparable
medical with baseline SCr vs 0.72, though 95% CIs
crossed) a ﬁnding commonly found reﬂecting overﬁt-
ting from derivation design or modelling (sample size
Figure 3 Calibration plots of predicted probabilities versus observed rates of HA-AKI. Predicted probabilities versus observed
rates (HA-AKI) at each level of the APS score in the medical (TOP) and surgical (BOTTOM) cohorts with a known baseline
creatinine. APS, acute kidney injury (AKI) prediction score; HA-AKI, hospital-acquired AKI.
Table 2 Risk range for HA-AKI by APS in validation study versus original derivation study
Validation Derivation study
APS points HA-AKI OR* HA-AKI OR*
0–2 4% 0.4 (0.3 to 0.5) 3% 0.29 (0.17 to 0.49)
3–4 8% 2.2 (1.6 to 2.9) 7% 2.3 (1.3 to 4.1)
5–6 14% 2.3 (1.8 to 2.9) 19% 4.4 (2.7 to 7.1)
≥7 28% 4.7 (3.1 to 7.2) 33% 6.7 (2.5 to 18.3)
*OR (95% CIs).
APS, acute kidney injury (AKI) prediction score; HA-AKI, hospital-acquired AKI.
Hodgson LE, et al. BMJ Open 2017;7:e013511. doi:10.1136/bmjopen-2016-013511 5
Open Access
Library. Protected by copyright.
 o
n
 O
ctober 10, 2019 at Periodicals Departm
ent G
eorge Edwards
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-013511 on 8 March 2017. Downloaded from 
and selection of variables) and clinical factors such as
case mix.23 33 35 However, the observed rates of HA-AKI
(8.1% vs 7.2% in the derivation) and associated
inpatient mortality were similar in those with the
outcome (20.5% vs 21.5%) and those without the
outcome (3.5% vs 4.5%) in derivation and validation
cohorts, respectively. The validation cohort was older
and had higher rates of diabetes and heart failure
whereas in contrast, rates of CKD and liver disease were
lower. The two physiological observations included in
the APS (reduced level of consciousness and tachyp-
noea) were also less commonly abnormal in the
validation cohort (see online supplementary appendix
table A2 for summary).
Different methods were used in the two studies, for
example, to deﬁne CKD (eGFR >1 and <6 months prior
to admission in derivation vs national baseline in this
external validation). It is unclear to what extent this
would have affected the results, though patients could
conceivably have already developed AKI in the commu-
nity. For example, if the last available SCr was a number
of months ago, HA-AKI may be overestimated and
CA-AKI underestimated. The validation uses the prag-
matic national baseline deﬁnition that will be applicable
in clinical practice and allows automation in an elec-
tronic hospital system. The original APS study had rela-
tively few events per variable, as well as high weighting
for two infrequent variables (liver disease and conscious
level) that may account for reduced model performance
in validation. In the larger validation population these
variables, though still signiﬁcant, were rarely present.
Furthermore, the derivation cohort included patients
who had more than one admission, while the external
validation cohort included only ﬁrst admission during
the study period. Patients with recurrent admissions may
have been prone to recurrent AKI episodes, and in par-
ticular a prior episode of AKI could be incorporated to
improve model prediction. This is an area of future
interest.
However, currently employed statistical markers of per-
formance also have limitations. Correctly predicting a
future event is more complex than diagnostic prediction
models, partly due to the time elapsed between predic-
tion and outcome, with a signiﬁcant stochastic element
and therefore accurate risk stratiﬁcation is often the best
that can be achieved. AKI, deﬁned by a nominal change
in SCr, may be the manifestation of a number of acute
precipitants (eg, sepsis, vomiting) affecting a susceptible
host (eg, a patient with heart failure and reduced
physiological reserve), making accurate prediction at a
single time period (hospital admission) with high dis-
crimination, impossible.36 37 Given there is no consensus
on what constitutes acceptable discrimination, descrip-
tors such as ‘poor’ or ‘good’ to a particular AUROC are
often ascribed, but the AUROC has shortcomings
including a narrow focus on accuracy that may not
incorporate information on consequences.38–40 For
example, if a false-negative result is more harmful than a
false-positive result, a model with much greater speciﬁ-
city, but slightly lower sensitivity than another would
have a higher AUROC, but may be a poor clinical
choice.41 With the assumption of uniform distribution of
risk, the maximum AUROC is 0.83.42 In a perfectly cali-
brated model in a population with an average 10-year
risk of 10% with relatively little spread, risk is centred
around 10%, and the maximum AUROC is 0.63.40
Though calibration is often overlooked, it is crucial in
risk prediction,40 43 and in this validation the calibration
plots suggest adequate ﬁt between predicted probabil-
ities and observed frequencies of clinical value. More
nuanced alternatives are yet to be widely used.41 44 45
Potential clinical use of the APS
First, using risk ranges, an APS score of 0–2 points
(encompassing 36% all medial patients with a baseline
SCr) was associated with a low risk of HA-AKI (4%),
while a score ≥7 points had a 28% risk.
Second, at ﬁve APS points (18% of patients) PPV was
relatively low (16% (13–18%)), however, the high NPV
94% (93–95%) suggests an ability to identify those at
low risk (as rule out) and importantly even if HA-AKI
developed patients (with an APS <5 points) were signiﬁ-
cantly less likely to die than those with a higher APS.
Third, with only seven variables the APS is relatively
simple to calculate. Fourth, all variables can potentially
be automatically calculated in (the increasing number
of) hospitals with electronic records containing clinical
coding and physiological observation systems.
Fifth, the score in this validation performed with
similar discrimination in two other cohorts—general
surgery and in patients without a baseline SCr.
Finally, the score has potential as an aid memoire to
variables associated with HA-AKI, consistently found on
systematic review of other AKI prediction models.46
Alternative models
Appraising other models can inform whether a model is
worth further investigating or implementing, or high-
lighting well developed, validated alternatives. In the
ﬁeld of HA-AKI prediction only one other model for
general emergency medical and surgical admissions
from the UK study (to predict HA-AKI at 72 hours) has
external validation evidence, with an AUROC of 0.67 in
derivation and 0.71 in external validation.29 The vari-
ables included (age, previous admissions, admission
diagnostic category, seven laboratory parameters,
Charlson comorbidity index and proteinuria) may be
difﬁcult to automate and inclusion of admission diagno-
ses is a shortcoming if use is required at the earliest
opportunity. Two older studies, one a retrospective
cohort and the other including 27 variables have not
been externally validated.27 28 Importantly all three
models may be difﬁcult to calculate at the bedside. (see
supplementary appendix table A3 for a summary of
these models with a corresponding Transparent
Reporting of a multivariable prediction model for
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Individual Prognosis Or Diagnosis (TRIPOD) guidance
reporting score.22
A large number of postsurgical models have been
derived principally in cardiac and transplantation
surgery, although the outcome is often the use of renal
replacement therapy with its inherent ﬂaws and indeed
when KDIGO AKI deﬁnitions have been used in exter-
nal validations AUROCs range from 0.61 to 0.74.47–51 In
contrast-induced AKI several models have been devel-
oped, however, most use specialty speciﬁc variables limit-
ing extrapolation to a general population.46 In patients
with acute heart failure the single externally validated
model produced an AUROC of 0.65 in both external
studies.52 53 The only externally validated general surgi-
cal model derived in the USA had an AUROC of 0.66
when transported to a Chinese population.54 Finally the
UK study in Trauma and Orthopaedics performed
external validation in the same publication, reporting
an AUROC of 0.70.55 Thus, in a number of ﬁelds
externally validated prediction models for HA-AKI are
relatively rare and have moderate discriminatory
performance.
Study strengths
This large study is one of the few external validations in
general populations.
In England, for example, general medicine, surgery
and orthopaedics are the three most common divisions
under whom patients are admitted.56 Though few
studies break down HA-AKI by specialty, two UK teach-
ing hospital studies suggested over half AKI episodes
were in these general specialties.57 58 Stringent inclusion
criteria (stayed at least one night, repeat SCr per-
formed), would have excluded a large proportion of
‘low-risk’ patients, recognised as such by the clinical
team, making the group in question of clinical rele-
vance. Using only the ﬁrst admission during the study
period avoids for the effects of recurrent admissions. It
is likely those with multiple attendances would be at
higher risk of HA-AKI as well as scoring higher on the
APS which takes into account age and (coded)
comorbidities, associated with an increased risk of read-
missions.59–62 Model updating could be assess the effects
of a prior episode of AKI, for example. While discrimin-
ation of a single admission APS score was only moderate,
this represents a single time point and from an outcome
that could occur up to 7 days later. If, for example, a
physiological deterioration occurred following admission
(with tachypnoea or reduced conscious level) this would
be reﬂected in a higher APS. Patients without a known
baseline SCr (a quarter of the medical cohort) pose par-
ticular problems: ﬁrst, CKD contributes to the APS and
second assessment of whether the AKI was community
or hospital acquired in nature is more difﬁcult. Such
patients in general would be lower risk than those with
recent available results as the latter would be more likely
to have been having tests to monitor chronic disease or
prior illnesses. The study demonstrated that in this
cohort the APS had similar performance to those with a
known baseline SCr.
Study limitations
The single-centre nature of the cohort cautions against
generalisability. Also although data were collected in a
prospective nature by the electronic hospital record,
past medical histories relied on previously coded events
on the hospital database, thus they are likely to under-
estimate disease prevalence. This could be addressed by
(planned) improved linkage with primary care databases
that could also incorporate information on medications.
Moreover, the validation site is in the same geographical
area to the derivation site and though overall a more
afﬂuent population bears similarities (elderly population
on the South East coast of England) that may not make
the results widely generalisable. Furthermore, relying on
a baseline SCr that could have last been measured a
number of months ago means that a proportion of the
patients considered to have HA-AKI may well have
already fulﬁlled the criteria for a change in SCr prior to
admission, that is, have CA-AKI, which could also be
true of those without a baseline SCr.
Future directions
Prediction of AKI remains of key importance given its
association with a high risk of mortality and in survivors,
high morbidity.16 Further external validation of predic-
tion models, with updating where necessary is desir-
able.22 Unfortunately, as AKI is a syndrome reﬂecting
diverse underlying pathophysiological states (usually)
imposed on a host with chronic disease, any model at a
single time point, is unlikely to predict with high dis-
crimination. Improving models will require comprehen-
sive records (medical and medications through primary
care linkage) with ﬂuctuating physiological trends (and
potentially laboratory parameters), mirroring the trad-
itional clinical approach to prognosis, with adherence to
enablers of clinical uptake.63 64 Complex models may
enable personalised risk stratiﬁcation, however, manual
inputting or use of a calculator without automation are
barriers to bedside use. A balance between comprehen-
sive risk factor inclusion, bedside usability and auto-
mated functionality must thus be struck. Drawbacks of
using urine output and SCr known to be unpredictably
affected by diverse inputs suggest that the employment
of more reﬁned biomarkers as predictors and markers
of signiﬁcant AKI are required.65 Finally, no AKI predic-
tion models have undergone impact analysis to assess
whether implementation can improve outcomes and this
is an area of interest. As no single intervention has been
found to improve outcome in AKI, a model would most
likely to be used as a part of a systematic alert to risk
and initiation of enhanced monitoring in the appropri-
ate clinical location with avoidance of iatrogenic harm.
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CONCLUSION
The APS to predict HA-AKI in an external validation
study of general medical and surgical patients per-
formed with moderate discrimination and acceptable
calibration. The prediction rule could help identify at
admission those patients at higher risk of developing
HA-AKI, in order to prevent its occurrence and avoid, or
at least mitigate associated signiﬁcant complications.
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